Display options
Share it on

Case Rep Dermatol. 2018 Feb 08;10(1):24-28. doi: 10.1159/000487002. eCollection 2018.

Giant Congenital Melanocytic Nevi: An Update and Emerging Therapies.

Case reports in dermatology

Girish Gulab Meshram, Neeraj Kaur, Kanwaljeet Singh Hura

Affiliations

  1. aDepartment of Pharmacology, Postgraduate Institute of Medical Education and Research and Dr. Ram Manohar Lohia Hospital, New Delhi, India.
  2. bDepartment of Radiology, The University of Texas Health Science Center, San Antonio, TX, USA.
  3. cDepartment of Pediatrics, Richmond University Medical Center, New York, NY, USA.

PMID: 29515391 PMCID: PMC5836163 DOI: 10.1159/000487002

Abstract

Giant congenital melanocytic nevi (GCMN) are a rare occurrence. Gain-of-function mutation in the NRAS gene is found to be associated with GCMN, causing abnormal proliferation of embryonic melanoblasts. The two major complications associated with GCMN are malignant melanoma and neurocutaneous melanosis. Treatment of GCMN has conventionally been surgical. However, the role of NRAS inhibitors and inactivation of nevus tissue by high hydrostatic pressure are being explored. We present a case of a 1-day-old neonate born with GCMN, along with a review of the literature.

Keywords: Giant congenital melanocytic nevi; Malignant melanoma; Neurocutaneous melanosis

References

  1. J Invest Dermatol. 2017 Nov 11;:null - PubMed
  2. JMIR Res Protoc. 2016 Aug 11;5(3):e162 - PubMed
  3. Pediatr Med Chir. 2012 Mar-Apr;34(2):73-6 - PubMed
  4. An Bras Dermatol. 2013 Nov-Dec;88(6):863-78 - PubMed
  5. Pediatr Neonatol. 2010 Feb;51(1):61-4 - PubMed
  6. J Invest Dermatol. 2014 Apr;134(4):879-882 - PubMed
  7. Actas Dermosifiliogr. 2017 Nov;108(9):e57-e62 - PubMed
  8. PLoS One. 2017 Nov 1;12 (11):e0186958 - PubMed
  9. J Am Acad Dermatol. 2017 Apr;76(4):689-694 - PubMed
  10. Plast Reconstr Surg Glob Open. 2015 Aug 10;3(7):e469 - PubMed

Publication Types